Brief: Genmab Presents Phase 3 Data from EPCORE FL-1 Trial
Dec 8(Reuters) - Genmab A/S GMAB.CO: SAID ON SUNDAY TRIAL RESULTED IN STATISTICALLY SIGNIFICANT, CLINICALLY MEANINGFUL REDUCTION IN THE RISK OF DISEASE PROGRESSION OR DEATH AND OVERALL RESPONSE COMPARED TO R2 ALONE Source text for Workspace: ID:nGNE84hcLD Further company coverage: GMAB.CO (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Genmab A/S
See all newsBrief: Genmab Says Orbis Investment Management Holds 4.99% Of Genmab Voting Rights As Of June 12
Brief: Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Brief: Genmab Presents Epcore Fl-1 Data Showing Consistent Efficacy, Safety For Epcoritamab Combination
Brief: Genmab Says Orbis Investment Management Limited Holds 5.08% Of Genmab A/S As Of May 8, 2026
Genmab falls after 'uneventful' Q1, profit miss